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Abstract
Background: In several species, considerably higher levels of estradiol-17 (E2) are synthesized in the CL. E2 has
been suggested to participate in the regulation of luteal steroidogenesis and luteal cell morphology. In pregnant
rats, several experiments have been carried out to examine the effects of inhibition of luteal E2 synthesis on CL
structure and function.
Methods: During days 12–15 of pregnancy in rats, luteal E2 was inhibited by way of daily oral administration of
anastrozole (AI), a selective non-steroidal aromatase inhibitor, and experiments were also performed with E2
replacement i.e. AI+ E2 treatments. Luteal tissues from different treatment groups were subjected to microarray
analysis and the differentially expressed genes in E2 treated group were further examined for expression of
specific E2 responsive genes. Additional experiments were carried out employing recombinant growth hormone
preparation and flutamide, an androgen receptor antagonist, to further address the specificity of E2 effects on the
luteal tissue.
Results: Microarray analysis of CL collected on day 16 of pregnancy post AI and AI+E2 treatments showed significantly
lowered cyp19a1 expression, E2 levels and differential expression of a number of genes, and several of them were
reversed in E2 replacement studies. From the differentially expressed genes, a number of E2 responsive genes were
identified. In CL of AI pregnant rats, non-significant increase in expression of igf1, significant increase in igbp5, igf1r and
decrease in expression of Erα were observed. In liver of AI treated rats, igf1 expression did not increase, but GH
treatment significantly increased expression that was further increased with AI treatment. In CL of GH and AI+GH
treated rats, expression of igfbp5 was higher. Administration of flutamide during days 12–15 of pregnancy resulted in
non-significant increase in igfbp5 expression, however, combination of flutamide+AI treatments caused increased
protein expression. Expression of few of the molecules in PI3K/Akt kinase pathway in different treatments was
determined.
Conclusions: The results suggest a role for E2 in the regulation of luteal steroidogenesis, morphology and proliferation.
igfbp5 was identified as one the E2 responsive genes with important role in the mediation of E2 actions such
as E2-induced phosphorylation of PI3K/Akt kinase pathway.
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Background
In several species, the control of corpus luteum (CL)
function is broadly accomplished by the dynamic inter-
play between luteotrophic and luteolytic factors. Of the
several luteotrophic factors, three key hormones namely,
LH, PRL and E2 play critical role and depending on the
species, they act to function individually or as a part
of the luteotrophic complex to regulate luteal function
[20, 28, 36]. Interestingly, all three hormones have been
recognised for their trophic actions on structure and func-
tion of CL in rats. Studies in rabbit were the first to
propose the luteotrophic effects of E2 [15]. Expression of
Cyp19a1gene that encodes the aromatase enzyme respon-
sible for aromatization of androgens into estrogens in the
luteal tissue of both pregnant and pseudo pregnant rabbits
has been reported [1]. The rat CL is unique in that expres-
sion of Cyp19a1is highest, and it has been reported that
androgens synthesized in placenta are transported to CL
for aromatization into E2, since placenta lacks Cyp19a1ex-
pression [19, 40]. Even though the CL of several species is
capable of E2 biosynthesis and express estrogen receptors
ERα and ERβ [3, 33, 34], elucidation of direct effects of E2
on CL function has received little attention. Since the rat
CL has high capacity for E2 biosynthesis, the intraluteal
effects of E2 will be expected to be pre-eminent. In rats, E2
has been reported to have multiple effects on CL function
that range from transport of cholesterol for P4 biosyn-
thesis, hypertrophy of luteal cells, conversion of small lu-
teal cells into large luteal cells [35, 36]. However, the
mechanism/s by which E2 mediates these effects in the lu-
teal tissue is poorly understood. In a recent study from
our laboratory, differential expression of many E2 respon-
sive genes in the luteal tissue was observed during induced
luteolysis in two distinct animal models, macaque and the
bovine species [32]. In that study, it was observed that
following rapid decline in circulating and luteal E2 levels,
many of the genes belonging to the IGF system were dif-
ferentially expressed. The components of IGF system
which consists of two ligands (IGF1 and IGF2), two recep-
tors and at least six IGF binding proteins (IGFBP1-6) are
increasingly being implicated in the control of CL func-
tion. In the present study, a number of experiments were
carried out to test the hypothesis that E2 plays a critical
role in the maintenance of luteal function in rats. Inhib-
ition of E2 was accomplished by administration of specific
aromatase inhibitor (AI)..In this study microarray analysis
was performed to examine differential expression of E2
responsive genes with a view to address critical issue of
specific effect/action of E2 on CL function. The results
suggest involvement of IGF system, especially changes in
expression of IGF1 and IGFBP5 during E2 inhibition and
replacement studies. In several species, GH plays a key
role in multiple physiological processes largely mediated
by increasing IGF1 levels in liver [42]. However, the
receptor for GH is expressed in several tissues including
the CL [4]. Since IGF1 gene transcription is rapidly and
profoundly induced by GH through activation of STAT5b
[39], it became to interest to examine the effect of GH on
the expression of igf1 in liver and CL during E2 inhibition
and replacement experiments. Further, we examined
whether IGFBP5 participates in mediating E2 actions. The
results suggest novel roles for IGFBP5 during proliferation




Anastrozole, a selective non-steroidal aromatase inhibi-
tor (AI), 17-β estradiol, testosterone, flutamide and Oil
Red O stain were purchased from Sigma-Aldrich Co.,
Bangalore, India. Recombinant bovine growth hormone
(rbGH) was a kind gift from Monsanto Company St. Louis,
MO. Oligonucleotide and Oligo dT primers were synthe-
sized by Sigma-Genosys, Bangalore, India. DyNAzyme™ II
DNA polymerase was purchased from Finnzymes (Espoo,
Finland) and dNTPs were procured from Eppendorf,
(Hamburg, Germany). Power SYBR® Green PCR master
mix was obtained from Applied Biosystems, Foster City,
CA. The details of antibodies employed are provided in
Additional file 1: Table S1. The secondary anti-rabbit and
the ABC colour development kit was procured from
Bangalore Genei, India. Mouse/rat Insulin-like Growth
Factor-1 (m/r IGF-1) ELISA kit was procured from
BioVendor, Mediagnost, Germany. All other reagents
were purchased from Sigma-Aldrich Co., Bangalore,
India or sourced from local distributors.
Experimental protocol, CL and blood collection schedule
Rattus norvegicus (Harlan Wistar strain) were housed in
a controlled environment and kept under a light: dark
cycle of 12 h with ad libitum access to food and water.
To obtain pregnant animals, the vaginal smear of the
cohabitated females with males was screened daily for
presence of sperm and the day of appearance of
sperm was designated as day 1 of pregnancy. All pro-
cedures in animals were approved by the Institutional
Animal Ethics Committee, Indian Institute of Science,
Bangalore, India.
Experiment 1: In vitro aromatisation of testosterone (T)
during mid-pregnancy
To determine the activity of aromatase present in the
CL tissue and to examine the effectiveness of AI in
blocking aromatase activity, in vitro studies were per-
formed employing a previously published method [13]
with few modifications. CL from day 7, 11, 12 and 16 of
pregnant rats were incubated in vitro without or with T
or AI for examining the aromatization capacity during
Tripathy et al. Reproductive Biology and Endocrinology  (2016) 14:19 Page 2 of 16
different days of pregnancy. The individual CL was
weighed, sliced into pieces and ~ 10–12 mg pooled
tissue/well was used for studies. Tissue samples were
placed in wells containing 1 ml M199 containing
10 μl of propylene glycol (VEH) or AI (120 ng/well)
without or with T (20 ng/well) and incubated for 4 h
at 37 °C with 5 % CO2 for determining E2 levels in
the medium.
Experiment 2: Effect of inhibition of luteal E2 on structure
and function of CL during pregnancy
Experiments were carried out during early (day 7 to 11
of pregnancy) and mid (day 12 to 16 of pregnancy) preg-
nancies corresponding to low and high E2 secreting
phases. To determine the suitable dose of AI and
duration of treatment required for consistent inhibition
of luteal E2 synthesis in vivo, a pilot study was carried
out in which oral administration of various doses of
AI (0.1, 0.15, 0.5 and 1 mg/kgBW/day dissolved in a total
volume of 0.3 ml of water containing 2 % ethanol) admin-
istered on days 7–10 and days 12–15 of pregnancy. The
results of pilot study indicated that administration of AI at
a dose of 1 mg/kg BW/day on days 12–15 of pregnancy
significantly lowered circulating and luteal E2 levels on
day 16 of pregnancy. Also, the weights of CL were lower
and had evidence of loss of implantation.
To examine the effects of depletion of luteal E2 levels
on CL structure and function, groups of pregnant rats
(n = 4 animals/group) were orally administered VEH
(2 % ethanol) or AI (1 mg/kg BW) daily on days 7–11
(early pregnancy) and on days 12–15 (mid-pregnancy).
The details of experimental protocol, schedule of blood
sample collection, treatments and CL collection are
represented in Fig. 1a and b. Also, blood samples and
CL were collected from a group of untreated rats on
day 7 and 12 of pregnancy.
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E2 s.c./ GH (Growth Hormone) 4 mg/kg BW  inj. s.c./     
Flu (Flutamide) 15 mg/kg BW  inj. s.c.
CL collection Blood sampling •
D16 (VEH)
D16 (+AI)
D12 (VEH)  
Fig. 1 Effects of AI on circulating E2, luteal E2 and T, weight of CL and Cyp19a1 mRNA expression during mid pregnancy in rats. Experimental
protocols from Experiment 2–5 (A-C) in Rattus norvegicus. The CL and blood collection are indicated by a red star and dot, respectively. Pregnant
rats received oral administration of VEH (2 % ethanol) or AI (1 mg/kg BW) on day 7 (a) or 12 (b) for 4 days daily and blood and CL tissue samples
were collected on day 11 or 16. c Beginning on day 12, pregnant rats received oral administration of AI (1 mg/kg BW) and 5 μg E2 or 4 mg/kg
BW GH or 15 mg/kg BW Flu/am and pm, s.c. for 4 days daily. CL tissues collected on day 16 of pregnancy. d Mean±SEM serum E2 concentration
during different treatments (n = 4 animals/time point, one-way ANOVA, ***P <0.001). Two to three corpora lutea were processed for tissue lysate
preparation using sterile ice cold 1X PBS for quantitating luteal E2 (e) and T (f) concentrations. Each bar represents mean±SEM, n = 4 animals/time
point, one-way ANOVA, ***P <0.001. g Weight of CL during different treatments along with a representative photo for each treatment is shown
on each bar (mean±SEM, n = 12 CL/time point, one-way ANOVA, ***P <0.001). h qPCR expression of Cyp19a1 in CL post different treatments.
The results are shown as fold changes in mRNA expression compared with day 12 control. Individual bars represent mean±SEM fold change in
mRNA expression value for qPCR analysis during different treatments (n = 4 animals/time point, one-way ANOVA, ***P <0.001)
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Experiment 3: Effect of E2 replacement on the function of CL
during AI treatment
After confirming of significant inhibition of circulating
and luteal E2 concentrations and morphological changes
in CL post AI treatment (see results), further experi-
ments were carried out to identify the specific effects of
E2 on CL function and morphology. Groups of pregnant
rats (n = 4 animals/group) were administered AI+VEH
or AI+E2 (5 μg) as per the protocol provided in Fig. 1c.
Experiment 4: Effect of GH on expression of IGF1 and
IGFBP5
Since changes in IGF1 system were observed with AI
treatment, studies were conducted to examine GH ac-
tion on CL function. rbGH was administered at a dose
of 4 mg/kg BW s.c. twice daily without (i.e. VEH+GH)
or with AI treatment (AI+GH, n = 4 rats) during days
12–15 of pregnancy. Blood samples, CL and pieces of
liver were collected on day 16 for various analyses as per
the protocol provided in Fig. 1c.
Experiment 5: Effect of androgen receptor antagonist on
the function of CL in AI treated pregnant rats
AI treatment resulted in substantial increase in serum T
concentration. To examine whether androgens contrib-
uted to changes in CL function, experiments were car-
ried out using androgen receptor antagonist, flutamide
(Flu). Flu was administered at a dose of 15 mg/kg BW
s.c. twice daily without (i.e. VEH+Flu) or with AI treat-
ment (AI+Flu, n = 4 rats) during days 12–15 of preg-
nancy. Blood samples and CL were collected for various
analyses as shown in Fig. 1c.
Corpora lutea from experimental animals were isolated
from anesthetized animals for microarray and other ana-
lyses. For quantitating tissue E2 and T concentration,
two or three corpora lutea were processed for tissue
lysate preparation using sterile ice cold 1X PBS. For
histochemistry, two or three corpora lutea were fixed in
NBF solution. The remaining corpora lutea were stored at
−20 °C for cryosectioning or flash frozen in liquid nitrogen
and stored at −70 °C.
Hormone assays
Luteal and serum steroids (E2 and P4) were determined
by specific RIAs as reported previously [21, 32]. The
sensitivity for E2 and P4 in the assays was 39 pg/ml
and 0.1 ng/ml, respectively. The inter- and intra- assay
coefficient of variations for both E2 and P4 hormones
were <10 %. The concentration of serum and luteal T
was quantitated by a commercially available direct T
assay kit (Immunotech, Marseilles, France). The sensi-
tivity of the assay for T was 0.08 ng/ml. The inter- and
intra- assay coefficient of variations were 15 and
14.8 %, respectively.
Plasma IGF1 assay
Plasma IGF1 was quantified using a specific IGF1mouse/
rat ELISA kit. The assay utilizes two specific and high af-
finity antibodies for IGF1. The IGF1in samples bind to
the immobilized first antibody on the microtiter plate,
the biotinylated and streptavidin-peroxidase conjugated
second specific anti-IGF1antibody binds in turn to the
immobilized IGF1 To dissociate IGF1 from the IGFBPs,
plasma samples were diluted in acidic buffer provided
with the kit and the diluted samples were assayed in
50–100 μl as per the manufacturer’s protocol. The sensi-
tivity assay was 0.029 ng/ml. The inter- and intra- assay
coefficients of variation were 8.5 and 7.2 %, respectively.
RNA isolation
Total RNA was extracted from CL and liver tissues from
different experiments using TRI Reagent® according to
the procedure as reported previously [21].
cDNA preparation and Semi quantitative RT-PCR analysis
Total RNA was reverse transcribed using the following
protocol: 1 μg of total RNA along with 1 μl of Oligo dT
was incubated at 65 °C for 10 min and snap chilled on
ice for 5 min and 4 μl of 5× RT buffer containing
250 mM Tris HCl (pH 8.3 at 25 °C), 250 mM KCl,
20 mM MgCl2 and 10 mM DTT was added followed by
10 mM dNTPs, 20 units of ribonuclease inhibitor, DEPC
treated water to make the volume up to 19 μl and to it,
200 units (1 μl) of Revert Aid™ MMuLV Reverse tran-
scriptase was added. The reaction mixture was incubated
at 42 °C for 1 h. PCR was carried out using gene specific
primers. The efficiency of the RT-PCR was checked
using L19 expression, a house keeping gene. For PCR,
cDNA equivalent 25 ng of total RNA was used. The
PCR mix used in each reaction contained 0.2 mM
dNTPs, 2.5 μl of 10× buffer containing 100 mM Tris-
HCl pH 8.8 at 25 °C, 15 mM MgCl2, 500 mM HCl and
0.1 % Triton X-100; 25 μM each of forward and reverse
primers and 1 unit of DyNAzyme™ II DNA polymerase.
For selecting the annealing temperature, the temperature
gradient semi quantitative RT-PCR was performed as re-
ported previously [21].
qPCR analysis
The analysis was carried out essentially as described pre-
viously [29, 32]. The diluted cDNA samples equivalent
to 10 ng of total RNA were subjected to validation ana-
lysis on Applied Biosystems 7500 Fast Real Time PCR
system with SDS v 1.4 program employing Power SYBR
green 2× PCR master mix. The 10 μl qPCR mixture con-
tained cDNA equivalent to 10 ng of total RNA, 5 μl of
PCR master mix and 5 μM each of forward and reverse
gene specific primers. PCRs were carried out in dupli-
cates in 96 well plates. The initial enzyme activation was
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carried out at 95 °C for 10 min, denaturation was carried
out at 95 °C for 30 s, the annealing was carried out at
specific annealing temperature for 30 s and extension
was at 72 °C for 30 s with a final extension of 5 min at
72 °C. Analysis of expression of each gene included a no
template control (NTC) and generation of a dissociation
curve. Expression levels of the genes validated were nor-
malized by using L19 expression levels as calibrator or
internal control for each cDNA sample. Primers were
designed using rat (Rattus norvegicus) sequences submit-
ted at NCBI and ENSEMBL using Primer Express™ ver-
sion 2.0 (Applied Biosystems, Foster City, CA, USA).
The primers were designed to cover the exon-exon junc-
tions. The details of primers employed along with the
amplicon size and annealing temperature are provided
in Additional file 2: Table S2. Real time PCR efficiencies
were acquired by amplification of a standard dilution
series (with 10 fold differences) in the Applied Biosys-
tems 7500 Fast Real time PCR system with SDS v 1.4
program employing Power SYBR Green 2X PCR mix.
The corresponding efficiencies (E) for different gene
primers were calculated according to the equation:
E = 10[−1/slope] −1 [25] and an efficiency of >90 %
was obtained for all. Analysis of expression of each
gene included a no template control (NTC) and gener-
ation of a dissociation curve. Expression levels of the
genes validated were normalized by using L19 expression
levels as calibrator (internal control) for each cDNA sam-
ple. The relative expression and fold change in gene ex-
pression was determined using DCt and DDCt method,
respectively. Relative expression = 2-DCt and fold change =
2-DDCt, where Ct = Threshold cycle i.e. the cycle number
at which the relative fluorescence of test samples increases
above the background fluorescence, DCt = [Ct gene of
interest (unknown sample) - Ct of L19 (unknown sample)]
and DDCt = [Ct gene of interest (unknown sample) - Ct of
L19 (unknown sample)] - [Ct gene of interest (calibrator
sample) - Ct of L19 (calibrator sample)]. PCR for each
sample was set up in triplicates and the average Ct value
was used in the DDCt equation.
Microarray target preparation, hybridization and analysis
RNA samples from CL of animals of day 12 and day 16
(VEH, AI and AI+E2 treatment groups) of pregnancy were
subjected to microarray analysis. Three Affymetrix Rat
Gene 1.0 ST Arrays [transcript (gene) version] i.e. three
RNA samples from individual animals/group were used.
The detailed description of procedures and subsequent
generation of processed image files of microarray ana-
lysis reported previously for other species [29, 32]
were followed for this study. The microarray procedure
and data analysis were performed as per Minimum
Information About Microarray Experiments (MIAME)
compliance. The raw data and the completed analysis
of microarray data files have been deposited at NCBI’s
Gene Expression Omnibus (GSE41735). ‘R’ software ver-
sion 2.12.2/Bioconductor (FHCRC labs, Seattle, WA) was
used for RMA normalization and for identification of dif-
ferentially expressed transcripts. The statistical analysis
employed for analysing the differentially expressed genes
was essentially similar to the recently published work from
the laboratory [32]. The data analyzed by Bioconductor
analysis tool employing ≥2.0 fold change (except for identi-
fication of E2 target genes, in which changes >1.5 fold was
considered for analysis) cut off and statistical filters pro-
vided a number of differentially expressed genes and those
found common between different treatments (VEH, AI
and AI+E2 treatments). For validation of microarray ana-
lysis, eight genes were selected for qPCR analysis. The sta-
tistically significant (P <0.05) correlation between the two
analyses was determined as reported previously [32]. The
differentially expressed genes were clustered by hierarchy
analysis by GeneSpring analysis for all the probe sets of
each treatment group is represented as dendrograms (data
not shown). To examine molecular function and genetic
networks, microarray data was analyzed using Ingenuity
Pathway Analysis (IPA version 8.7, Ingenuity® Systems Inc.,
Redwood City, CA; http://www.ingenuity.com).
Analysis of expression of E2 responsive genes
To examine the role of E2 in the regulation of rat CL
structure and function, the differentially expressed genes
identified in CL of E2 inhibition (AI) and replacement
(AI+E2) groups were mined for E2 responsive genes. For
this purpose, 89 genes were chosen as E2 responsive genes
and the list of genes was same as previously reported for
another study relating to macaque and bovine CL [32].
Immunoblot analysis
CL tissue lysate preparation and immunoblot analysis
were carried out as per the previously published pro-
cedures [24].
Histology
Immunohistochemistry for ki67 was carried out on a piece
of ovary containing 2–3 CL as described previously [43].
Oil Red O staining
Pieces of ovaries containing at least 2–3 CL stored at
−20 °C were subjected to cryotome sectioning (~8 μm
thickness) and fixed in 10 % formalin for 5–10 min.
The sections were immersed in absolute propylene
glycol for 2–5 min followed by staining in 60 °C pre
heated Oil Red O stain for 8–10 min. The slides were
differentiated in 85 % propylene glycol for 2–5 min,
washed in distilled water and stained with hematoxylin
before mounting with glycerine jelly for observation under
inverted microscope.
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Statistical analyses
The hormone data, qPCR fold change expression data
among different experimental groups and densitometric
data are expressed as mean±SEM. For multiple compari-
sons, the data were analyzed by one-way ANOVA, followed
by Newman-Keuls multiple comparison test (PRISM Graph
Pad, version 5; Graph Pad Software, Inc., San Diego, CA).
Comparisons between mean of two groups were carried
out using Student t-tests. A P value of <0.05 was considered
to be statistically significant.
Results
Analysis of in vitro aromatization in CL tissue
The results indicated that although basal E2 secretion
from CL tissue slices on different days did not change, but
addition of T resulted in significant increase in E2 secre-
tion. Furthermore, addition of AI had no effect on basal
E2 secretion, but inhibited T conversion to E2 from tissue
slices of day 16 pregnancy (Additional file 3: Figure S1A).
AI treatment on CL function during early pregnancy
Circulating E2 levels on day 11 following AI treatment
on days 7–10 of pregnancy was 68.2 ± 3.89 pg/ml which
was significantly lower (P <0.05) compared to VEH
treated animals (82.8 ± 3.98 pg/ml, Additional file 3:
Figure S1B). Circulating P4 levels (64.5 ± 2.72 vs. 70.0 ±
1.78 ng/ml), CL weight (2.19 ± 0.12 vs. 2.16 ± 0.09 mg/CL)
and Cyp19a1 mRNA expression (Additional file 3: Figure
S1C-E) were not significantly different between AI and
VEH treated animals. Based on these findings, further
studies employing AI treatment were not carried out
during early pregnancy.
AI treatment on CL function during mid pregnancy
Serum P4 concentration was significantly higher on day
16 VEH treated group (113.75 ± 5.54) compared to day
12 (74.5 ± 2.22) pregnant rats (Fig. 2a). The P4 concen-
tration did not increase in AI treated group (Fig. 2a).
Serum E2 concentration decreased significantly after AI
treatment [141.25 ± 5.15 (VEH) vs. 68.5 ± 2.53 (AI) pg/
ml, Fig. 1d]. Further, luteal E2 levels were significantly
lower in AI treated animals [6.15 ± 0.58 pg/mg CL vs.
19.27 ± 2.43] compared to VEH treated group, Fig. 1e,
while luteal T levels were significantly higher (11.37 ±
1.14 pg/mg CL) post AI treatment (Fig. 1f ). AI treatment
caused a significant decrease in CL weight (2.86 ± 0.17
vs. 4.82 ± 0.18 mg/CL for AI and VEH treated groups,
respectively, Fig. 1g) and decrease in Cyp19a1 mRNA
expression (Fig. 1h).
Replacement of E2 during AI treatment
Co-administration of E2 during AI treatment on day 12–
15 of pregnancy significantly increased P4 concentration
(Fig. 2a). The weight of CL in AI+E2 treated animals
(4.75 ± 0.32 mg/CL) was not significantly different from
the VEH treated group (4.82 ± 0.18 mg/CL), but higher
than AI+VEH treated group (Fig. 2b). The aromatase
protein level was low in CL of day 12 pregnancy, but
was higher in CL of day 16 VEH treated group (Fig. 2c).
AI treatment significantly decreased the aromatase level
compared to day 16 VEH treated group (Fig. 2c). Co-
administration of E2 during AI treatment prevented the
inhibition of aromatase level (Fig.2c; luteal E2 levels 21.5
± 1.56 pg/mg CL). Cyclin D1 levels were low on day 16
pregnancy and day 16 AI treated group, but was higher
in AI+E2 treated group (Fig. 2d). To further determine
E2 effect on cell proliferation, the cell proliferation
marker, ki67 expression was examined in the CL. The
intensity of expression was higher in CL of AI+E2
treated animals (Fig. 2e). The lipid content of luteal cells
was examined by oil red O staining and more lipid drop-
lets could be visualized in AI+E2 treated group (Fig. 2f ).
Microarray analysis of CL
The analysis at two fold cut off identified differential ex-
pression of 167 genes (73 and 94 genes, up and down
regulated genes) in CL of AI treated rats. Following AI
+E2 treatment, differential expression of 134 genes (81
and 53 up and down regulated genes) were identified
(Fig. 3a). The differential expression of 61 genes identi-
fied in AI treated group was reversed in AI+E2 treated
group. The list of differentially expressed genes in the
microarray data with >1 fold cut off was used with a view
to select maximum number of differentially expressed E2
responsive genes for purpose of carrying out pathway
analysis. The number of up and down regulated genes
and the number of commonly regulated genes between
AI and AI+E2 treated groups are presented in Fig. 3a.
From the differentially expressed genes, eight genes
were subjected to qPCR analysis to validate the micro-
array data and the results are presented in Fig. 3B. The
goodness of fit analysis of the data yielded a good cor-
relation coefficient ‘r’ values for AI [0.7349 (P = 0.0378)]
and AI+E2 [0.7372 (P = 0.0369)] treatments which sug-
gested that qPCR data corroborated well with the micro-
array data (Fig. 3c).
Pathway analysis of microarray data
The ingenuity pathway analysis (IPA) software was used
to classify the differentially expressed genes (1.5 fold cut
off ) into different function and disease categories. The
IPA analyses revealed that 85–90 % of the differentially
expressed genes were function or pathway eligible. Nine
networks were identified with score and number of focus
molecules ranging from as low as one to as high as 22.
The details of different networks for AI and AI+E2 treat-
ment groups are highlighted in Additional file 4: Table S3
and Additional file 5: Table S4. The IPA software analysis
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indicated that six networks (network #1, 2, 3, 5, 6 and 8)
for VEH vs. AI treatment and four networks (network #2,
3, 7 and 8) for AI vs. AI+E2 treatment were found to over-
lap with each other directly or indirectly. The network se-
lection was further categorized into differentially regulated
genes associated with E2 target (Fig. 4), steroidogenesis
(Additional file 6: Figure S2A) and growth factors
(Additional file 6: Figure S2B) with 26, 26 and 16
focus molecules, respectively. The findings emphasize
the role for E2 in the regulation of CL function.
Expression of E2 responsive genes in the pregnant CL
All 89 genes that were regarded as E2 responsive genes
were identified to be differentially expressed post AI and
AI+E2 treatments. There were 41 (up) and 48 (down) genes
differentially expressed post AI treatment. Following E2 re-
placement, 38 (up) and 51 (down) E2 responsive genes
were differentially expressed compared to AI treated group.
Venn diagrams were constructed to highlight those genes
whose expression pattern was reversed in CL of animals
receiving AI+ E2 treatment (Fig. 5a). As many as 56 genes
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Fig. 2 Effects of luteal E2 inhibition and replacement of E2 on serum P4, CL weight, aromatase expression, cyclin D1, ki67 and luteal lipid droplets
content. Beginning on day 12, pregnant rats received daily oral administration of AI (1 mg/kg BW) and 5 μg E2 (am and pm), s.c. for four days. CL
tissues collected on day 16 of pregnancy were subjected to microtome and cryosectioning. a Circulating mean serum P4 concentrations during
different treatments (n = 4 animals/time point, one-way ANOVA, ***P <0.001). b Weight of CL during different treatments with representative
photo is shown for AI and AI+E2 treatments. Each bar represents mean±SEM, n = 12 CL/time point, one-way ANOVA,
***P <0.001. Protein levels of
aromatase (c) and cyclin D1 (d). Protein lysate (50 μg) prepared from CL tissue from different treatments were resolved on 10–12 % SDS PAGE,
transferred onto PVDF membrane and immunoblot analysis was performed using antibodies against aromatase, cyclin D1 and β-actin. A
representative immunoblot for each antibody probed is shown. The immunoblot probed with β-actin antibody was used as loading control for each
lane. Each bar represents the fold change (mean±SEM; n = 4 animals/time point) with respect to day 16 VEH treated CL, relative to intensity of β-actin
for each treatment (one-way ANOVA, ***P <0.001, **P <0.01). e Photomicrographs represent ki67 immunostaining of CL tissue sections post different
treatments. Samples were counter stained with haematoxylin, and images taken at a magnification of 20×. For reference, an image for the negative
control is shown. f Representative image of cryosectioned CL tissue sections for oil red O staining across different treatments. Arrow heads indicate cells
stained for lipid content
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[30 (up) and 26 (down)] were found to have their expres-
sion pattern reversed in AI+E2 treated rats (Fig. 5a). The
initial analysis highlighted a set of authentic E2 responsive
genes and a few of these genes were selected for further
analysis. The list of top 15 up and down differentially
expressed genes regarded as E2 responsive genes both
in AI and AI+E2 treatment groups are provided in
Additional file 7: Table S5 and Additional file 8: Table S6.
Hierarchical clustering of E2 regulated genes
A dendrogram (heat map) view produced by hierarchical
clustering of E2 regulated genes from AI and AI+E2
treatments is represented in Fig. 5b. Further, top 40 dif-
ferentially expressed E2 responsive genes were used to
construct heat map as in Fig. 5c. The differentially
expressed genes belonging to IGF system were selected
for further studies.
Effects of AI and AI+E2 treatment on the IGF system in the CL
Figure 6 shows protein levels for IGFBP5, IGF1, pPI3K
p85 and pAKT in the luteal tissue of AI and AI+E2
treated rats. IGFBP5 levels increased (Fig. 6a) and IGF1
levels decreased (Fig. 6b) in AI treated rats, but these
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Fig. 3 Schematic representation of temporal changes in differentially expressed genes and validation of microarray data of select genes by qPCR
analysis. a Bar graphs representing the number of differentially expressed genes identified after microarray analysis of CL tissues collected from rats
treated with VEH, AI & AI+E2 treatments. Data analyzed by Bioconductor analysis tool employing ≥2 and ≥1.5 fold change cut-offs. A comparison of
total number of up regulated and down regulated genes between VEH vs. AI (orange bars) and vs. AI+E2 (green bars). The commonly regulated genes
post E2 deprivation whose expression reversed with E2 replacement is represented by filled bars. b The fold change expression (microarray data) of
selected up and down regulated genes associated with specific biological process at AI and AI+E2. These genes were also subjected to qPCR analysis
and log2 (fold change) expression. Individual bars for each gene represents mean±SEM values in mRNA expression for microarray analysis (blue bars)
and qPCR analysis (yellow bars) during different treatments (n = 3 for microarray analysis and n = 4 for qPCR analysis. Upper panel, VEH vs. AI and lower
panel, VEH vs. AI+E2.
***P <0.001, **P <0.01, *P <0.05). Individual bars for each gene represents mean±SEM values in mRNA expression for microarray
analysis (blue bars) and qPCR analysis (yellow bars) during different treatments (n = 3 for microarray analysis and n = 4 for qPCR analysis. ***P <0.001,
**P <0.01, *P <0.05). c Correlation analysis between expression ratios obtained from microarray and qPCR analyses of few genes post different treatments
(n= 8 genes/treatment). Linear regression analysis was performed for selected differentially expressed genes using qPCR fold change in expression values
(2-ΔΔCT; Y-axis) with fold change expression values obtained by microarray analysis (X-axis). The r value, correlation coefficient, generated for the
theoretical line of best fit (represented as solid line in each panel) and the P value indicates significance of the correlation as determined by ‘F’ test
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with AI (Fig. 6a and b). Analysis of signalling molecules
downstream of both E2 and IGF signalling revealed that
AI treatment significantly lowered IGF1 (Fig. 6b), pPI3K
p85 (Fig. 6c) and non-significantly decreased pAKT
levels (Fig. 6d) compared to VEH treatment, but these
effects were reversed in AI+E2 treated rats (Fig. 6b-d).
The distinct changes that follow post E2 inhibition in the
CL tissue may be triggered by up regulation of IGFBP5
levels and accompanying decrease in the IGF and ER
signalling (E2-ER/PI3K-Akt cascade). The results suggest
a key role for E2 and its regulation of IGF signalling in
the luteal tissue.
Plasma IGF1 levels and IGF1 expression in liver and CL
tissues
Treatment with AI had no effect on plasma IGF1 levels,
whereas GH treatment significantly increased IGF1
levels and also in rats receiving AI+E2 treatment (Fig. 7a).
A combination of AI+E2+GH increased IGF1 levels but
not different from rats receiving GH alone (Fig. 7a). In
the liver, IGF1 mRNA expression was higher in GH
treated rats and the protein levels were higher in both
GH and AI+GH treated rats (Fig. 7a), but no change in
IGF1 mRNA expression and protein levels were ob-
served in AI and AI+E2 treated rats (Fig. 7a).
Analysis of expression of genes associated with IGF
signalling during different treatments
Since changes in expression of Igfbp5, Erα and Igf1r in
CL of AI and AI+E2 treated rats were observed, effects
of GH on expression of these genes were examined. GH
treatment did not lead to significant increase in P4 levels
(110.8 ± 10.4 ng/ml) on day 16 of pregnancy compared
to VEH treated rats (105.2 ± 8.5 ng/ml). Administration
of combination of AI+GH treatments resulted in de-
creased P4 concentrations (68.4 ± 6.2 ng/ml). The luteal
ESTROGEN TARGET GENES
Fig. 4 Classification of differentially expressed genes into E2 target genes by Ingenuity Pathway Analysis (IPA). IPA of the differentially regulated
genes post AI treatment shows a network of 26 focus molecules. The network is displayed graphically as nodes (gene/gene products) and edges
(biological relationship between nodes). They are represented by different shapes with their expected regulation of a particular cellular or
biological function. The red and green nodes represent up and down regulated genes or their products. The intensity of node colour indicates
the abundance and various shapes of the nodes represent molecular class of the gene product. The solid lines indicate interaction of molecules
being discussed that have been validated through various experiments and reported in literature. On the other hand, the dashed lines are
tentative interaction which are not yet completely validated and are based on computationally designed programs
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weights were 3.9 ± 0.22 mg/CL and 3.4 ± 0.2 mg/CL fol-
lowing GH and AI+GH treatments compared to weight of
4.64 ± 0.12 mg/CL from VEH treated rats. GH treatment
increased Igfbp5 expression in CL (Fig. 7b), but combin-
ation of AI and GH did not further increase the Igfbp5 ex-
pression (Fig. 7b). The Erα expression was high in CL of
AI+GH treated rats, but was significantly higher in rats re-
ceiving GH treatment. Figure 7b shows expression of Igf1
and Igf1r mRNA in CL of rats receiving VEH, AI, AI+E2,
AI+GH and GH alone treatments during days 12–15 of
pregnancy. The Igf1 mRNA expression was significantly
higher only in GH treated rats compared to all other treat-
ments (Fig. 7b). Although Igf1r expression in CL was
lower in AI+E2 treated rats, but the expression remained
high in AI+GH and GH alone treated rats (Fig. 7b).
The protein levels of IGFBP5 and IGF1 in VEH treated
rats were set as 1 fold and levels in other treatment
groups were expressed in relation to the VEH treatment.
The IGFBP5 levels increased significantly in all treatment
groups (Fig. 7c). In the CL, IGF1 protein level did not in-
crease with AI treatment, but significantly increased with
GH treatment and was non-significantly higher in AI+E2
and AI+GH treated rats (Fig. 7c). However, in the liver tis-
sue IGF1 levels were highest in GH treated rats, but was
also higher in AI+E2 treated rats (Fig. 7a).
Effect of flutamide (Flu) on CL function
AI treatment caused increased circulating T concentra-
tion. Employing androgen receptor antagonist, Flu, experi-
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Fig. 5 Schematic representation and dendrogram generated after hierarchical clustering of differentially expressed E2 responsive genes during
different treatments. a Venn diagrams representing the number of differentially expressed genes post different treatments. Data was analyzed by
Bioconductor analysis tool. Thirty and 26 genes that were identified as up and down regulated after E2 inhibition that were identified as down
and up regulated with E2 replacement treatment. A comparison of total number of up and down regulated genes was done across AI (orange)
and AI+E2 (blue). b Heat map or combined tree of the hierarchy analysis (by clustering gene identity and conditions) for probe sets at each time
point. i.e. VEH vs. AI and AI vs. AI+E2. The plot includes two dendrograms- vertical dendrogram for gene identity, and horizontal for different
treatments. A visual dual colour code, red and green, is utilized to indicate relatively up or down regulation, respectively. Top of each dendrogram
shows the condition colour bar with the parameters in each interpretation. c Top 40, up and down regulated genes from the analysis were utilized to
construct heat map to get a view of the differentially regulated E2 regulated genes post different treatments. The top of each dendrogram shows the
condition colour bar. Hovering over the cells of the heat map, the normalized intensity values are represented in various shades of red and green
indicating relatively either up or down regulation, respectively. The row header shown on the right side represents the complete entity name or gene
symbol. The genes Cyp19a1, Igfbp5, Igf1, Igf1r, and Esr1 are further highlighted with red arrows
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androgen concentration contributed to changes in CL
weight and function. Serum T concentration for various
treatments are presented in Fig. 8a. Treatment with AI re-
sulted in significantly higher concentration of T compared
to VEH treatment (Fig. 8a). Co-administration of Flu with
AI treatment did not significantly alter T concentration
compared to AI treated rats. The weight of CL in Flu
treated rats was not significantly different from the VEH
treated rats [4.82 ± 0.18 (VEH) vs. 4.51 ± 0.16 mg/CL
(Flu)]. The mRNA expression of IGFBP5 was not signifi-
cantly higher compared to its expression in CL of VEH
treated rats (Fig. 8c). Surprisingly, increased expression of
IGFBP5 seen in AI treated rats was not observed in AI
+Flu treated rats (Fig. 8c). The protein levels of IGFBP5 in
CL of Flu treated rats were high in AI+Flu treated rats,
but was not statistically significant from the AI treated
group (Fig. 8d).
Discussion
In rats, the luteal maintenance of P4 synthesis during the
second half of pregnancy is a complex one involving sev-
eral players, of which E2 is regarded as an important
component. In the present study, the findings of P4 se-
cretion pattern in AI and AI+E2 treated rats were largely
in accordance with observations reported previously by
others employing hypophysectomized and hysterecto-
mized rat model system [11]. It should be pointed out
that [11] employed a very high dose of E2 in contrast to
the very low dose of E2 used in the present study that
was devoid of detrimental effects on the implanted em-
bryos. Nonetheless, the observation that E2 supplemen-
tation stimulated P4 secretion in the present study
confirms the findings of others [10, 16]. The reported
decreased luteal weight observed in hypophysectomized
and hysterectomized pregnant rats [9] was also observed
in AI treated rats in the present study, however co-
administration of E2 with AI treatment restored the lu-
teal weight to VEH treated rats. Gibori & Sridaran [9]
suggested that the decreased luteal weight in the hy-
pophysectomized and hysterectomized pregnant rats was
due to atrophy and that E2 administration restored luteal
weight without causing changes in cell number. How-
ever, based on the results of the present study, we sug-
gest that in addition to atrophy, the cell numbers would
also be affected due to E inhibition, since markers of cell
cycle and cell proliferation (Cyclin D1 and ki67) were
observed to be lower in CL of AI treated rats, but were
higher in AI+E2 treated rats. However, it remains to be
determined whether E2 inhibition following AI treatment
resulted in increased incidence of apoptosis. Moreover,
the weight of CL increases remarkably in size through-
out gestation in rats [14], which further suggests that
growth of the luteal tissue involves increase in size as
well as number of luteal cells. This conclusion is further
supported by observations that E2 besides being mito-


























































































































Fig. 6 Effects of E2 inhibition and replacement on protein levels of IGFBP5, IGF1, pPI3K p85, Total PI3K p85, pAkt and Total Akt. Day12 pregnant
rats received oral administration of AI (1 mg/kg BW) and 5 μg E2 (am and pm) s.c. twice daily. Protein levels of IGFBP5 (a), IGF1 (b), pPI3K p85 and
Total PI3K p85 (c), and pAkt and total Akt (d). Protein lysates (50 μg) prepared from CL tissue from different treatments were resolved on 10/12 %
SDS PAGE, transferred onto PVDF membrane and immunoblot analysis was performed using antibodies specific to each protein. A representative
immunoblot for each of the antibody probed is shown. The immunoblot probed with β-actin antibody was used as loading control for each lane
(same immunoblot was shown for panel A&C, since IGFBP5 and pPI3K p85 and total PI3K p85 were probed on the same blot). Each bar represents
the fold change with respect to day 16 VEH and indicated as mean±SEM (n = 4 animals/time point), relative to intensity of β-actin for each treatment
(one-way ANOVA, ***P <0.001, **P <0.01, *P <0.05). For pPI3K p85 and pAkt, densitometric values were determined relative to intensity of Total PI3k p85
and total Akt, respectively
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of PI3K-Akt kinase pathway, and E2 lack has been shown
to cause apoptosis [18, 30]. The results of E2 inhibition
and E2 replacement experiments suggest that E2 is critical
to CL function in pregnant rats.
To date, several expression profiling studies carried
out employing different aromatase inhibitors have been
reported for breast cancer lines and ovarian tissues [8].
However, this is the first study detailing global transcrip-
tome changes observed in CL following inhibition of
aromatase expression by systemic administration of aro-
matase inhibitor. In the present study, the microarray
analysis data revealed several differentially regulated
genes associated with pathways related to steroidogene-
sis, adipogenesis, cell growth, differentiation and apop-
tosis. Further, the microarray data of CL from E2
inhibited and E2 replaced animal models were utilized
for identifying differentially expressed E2 responsive
genes. Surprisingly, expression of number of E2 respon-
sive genes was found to be affected by inhibition of lu-
teal E2 and the expression of many of these genes was
reversed in the E2 replacement study. Recently, we re-
ported a list of differentially expressed E2 responsive
genes during the early time points of luteolysis in two
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Fig. 7 Circulating IGF1 levels and expression of IGF signalling molecules in liver and CL during different treatments. Day12 pregnant rats received
oral administration of VEH (2 % ethanol)/AI (1 mg/kg BW), 5 μg (am and pm) E2 s.c. and 4 mg GH/kg BW (am and pm), s.c. daily for four days.
a Upper panel, circulating plasma IGF1 concentrations during different treatments (n = 4 animals/time point). Individual bar represents mean±SEM
plasma IGF1 concentrations during different treatments, one-way ANOVA, ***P <0.001, **P <0.01, *P <0.05. a Middle panel, qPCR analysis of Igf1
mRNA. The results are shown as fold changes of mRNA expression during treatments compared to day 16 VEH. Each bar represents mean±SEM,
one-way ANOVA, ***P <0.001. a Lower panel, a representative immunoblot analysis of IGF1. β-actin was used as loading control for each lane. Each
bar represents the fold change with respect to VEH treated liver and indicated as mean±SEM (one-way ANOVA, ***P <0.001, *P <0.05 n = 4 animals/time
point) relative to intensity of β-actin for each treatment. b qPCR fold change expression of Igfbp5, Erα, Igf1 and Igf1r mRNA from different
treatment groups. The fold expression change for VEH was set as 1 fold change. Individual bars for each gene represents mean±SEM fold
change in mRNA expression for qPCR analysis during different treatments (n = 4, one-way ANOVA, ***P <0.001, **P <0.01, *P <0.05). c A representative
immunoblot analysis for IGFBP5 and IGF1 in CL during different treatments. β-actin was used as loading control for each lane. Each bar represents the
fold change with respect to VEH treatment and indicated as mean±SEM (n = 4 animals/time point), relative to intensity of β-actin for each treatment
(one-way ANOVA, ***P <0.001, **P <0.01)
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E2 either sparsely (cows) or more abundantly (macaques)
[32]. In that study, although the luteolysis was induced
by different methods in both the species, surprisingly a
rapid decline in luteal E2 was observed and that was ac-
companied by differential expression of a large number
of E2 responsive genes and several of those genes were
also differentially expressed in the CL of pregnant rat.
Based on these observations it can be concluded that E2
plays an important role in the regulation of luteal func-
tion, however, it should be pointed out that participation
of luteotrophic and luteolysis factors in each species is
distinct from the other and those factors largely deter-
mine the effect of E2 on the luteal function. The studies
on E2 inhibition and replacement experiments suggest
differential expression of several E2 responsive genes and
many of them were identified as members of IGF sys-
tem. The differential expression of IGFBP5 was further
examined with different treatments. Surprisingly, GH
also caused increased expression of IGFBP5 in the CL
tissue.
In the present study, few of the molecules associated
with the PI3K signalling pathway were examined. Al-
though the downstream targets of PI3K are many, but
Akt is regarded as the primary mediator of PI3K regulat-
ing cellular component that affect cell survival [31]. Our
findings that mechanisms associated with cell survival,
progression, etc., were affected due to E2 inhibition
further strengthens the hypothesis that E2 plays an im-
portant role in the regulation of CL function. The pres-
ence of androgen receptors in the rat CL and their
activation has been reported to be associated with inhib-
ition of apoptosis [16]. The incidence of apoptosis was
not examined in the present study; instead luteal weight,
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Fig. 8 Effects of luteal E2 inhibition, replacement and androgen receptor antagonist on serum T, CL weight, IGFBP5 mRNA and protein levels.
a and b circulating mean±SEM serum T concentrations and weight of CL during different treatments (n = 4 animals/time point and n = 12 CL/
time point for weight calculation one-way ANOVA, ***P <0.001). c qPCR expression analysis of Igfbp5 in CL post different treatments. The results
are shown as fold changes of mRNA expression compared with day 16 VEH group. Individual bars represents mean±SEM fold change during
different treatments (n = 4 animals/time point, one-way ANOVA, ***P <0.001). d Immunoblot analysis of IGFBP5. A representative immunoblot is shown.
β-actin was used as loading control for each lane. Each bar represents the fold change with respect to day 16 VEH and indicated as mean±SEM (n = 4
animals/time point), relative to intensity of β-actin for each treatment (one-way ANOVA, ***P <0.001). e Schematic representation of IGFBP5 modulation
of classical IGF and E2 activated signalling pathways in the rat luteal cell. Increased IGFBP5 levels as a result of E2 inhibition by AI causes decrease
in circulating IGF1 levels leading to decreased activation of IGF1R (a tyrosine kinase) resulting in decreased activation of PI3K and pAkt/PKB levels.
Simultaneously, due to unavailability of E2 leads to inhibition of PI3K/Akt signalling pathway and thus inhibiting the survival pathway. E2 17β-estradiol,
ER estrogen receptor, IGFBP5 insulin- like growth factor binding protein 5, IGF1 insulin like growth factor 1, IGF1R IGF1 receptor, Src non receptor protein
tyrosine kinase, SHC Src homology 2 domain containing transforming protein, GRB2 growth factor receptor bound protein 2, SOS Son of sevenless,
PI3K, phosphatidylinositol 3-kinase, Akt protein kinase B, p phosphate group, ERE estrogen response element, AI aromatase inhibitor, ns non-significant
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were determined. In so far as the protein level of
IGFBP5 is concerned, Flu treatment had no effect on
AI-induced IGFBP5 levels. These results suggest that
T does not participate in the regulation of IGFBP5 ex-
pression in CL. However, additional studies are required
to assess other effects of T on CL function.
The observations in the present study are one of the
first reports on IGFBP5 and IGF action on ERα activity
in CL that is mediated partly via PI3K/Akt pathway. In
the CL, the prominent IGFBP5 mRNA expression has
not been observed [6]. In the present study, a good asso-
ciation with changes in levels of E2 and expression of
IGFBP5 in the CL was observed. Since changes in few of
the molecules of PI3K/Akt signalling pathway were ob-
served, it remains to be determined whether expression
of IGFBP5 was regulated by the PI3K/Akt pathway. Earl-
ier reports have suggested that E2 synthesized from pla-
cental androgens in the luteal cells cause hypertrophy of
LLC population [12, 22]. Interestingly, mRNA expres-
sion for different members of IGF system show SLCs to
be the major source of IGF1 and IGFBP3 and five,
whereas, IGFBP2 and four are expressed approximately
to same extent in both SLCs and LLCs [7]. The findings
in the present study point to inhibition of hypertrophy
of SLC, brought about by lack of E2 biosynthesis. This
implies that E2 may affect IGF1 mRNA expression differ-
ently depending on whether the cells are proliferating. The
interaction between E2 and growth factor signalling path-
ways has been well established [41, 44]. Additional studies
are necessary to unravel whether regulation of CL function
also involves interaction between E2 and IGF1 signalling.
The additive or synergistic effects of IGF1 and E2 on cell
proliferation, tumor development, anti-apoptosis and vas-
cular protection have been well described [2, 37]. Based on
the observations, it appears that the non-genomic signal-
ling pathway activated by the phosphorylation of ERα in-
duced by E2 gets inhibited in the presence of AI perhaps
due to increased IGFBP5 expression [5]. PI3K/Akt pathway
has been further documented in ERα stabilization and hor-
mone dependent and independent ERα activation process
[17, 27].
The findings of the present study together with the ob-
servations by others [26] suggest influence of IGF on
ERα activity involving PI3K/Akt pathway. The findings
from this study suggest inhibitory effect of IGFBP5 on
E2 induced ERα function is perhaps by way of sequestra-
tion of IGF1. The increased expression of PI3K/Akt sig-
nal pathway genes is suggestive of increased anabolic
metabolism, cell proliferation and survival [23, 38]. Fi-
nally, in the present study, the changes observed in the
CL are associated with presence or absence of E2, but
not by its substrate, androgen. Based on findings in this
study and others, we propose a model for E2 actions and
is represented in Fig. 8e.
Conclusion
In conclusion, the role of E2 in the regulation of luteal
steroidogenesis, hypertrophy and proliferation of cells in
the luteal tissue was analysed, and IGFBP5 was identified
as one of the E2 responsive genes that play an important
role in the mediation of E2 action perhaps due to the
E2-induced phosphorylation of PI3K/Akt pathway.
Additional files
Additional file 1: Table S1. List of antibodies used for immunoblot
analyses in rats. The list of antibodies employed in the immunoblot
analyses including the target sequence, antigen sequence, catalog
number, species raised in, dilution used, molecular weight and
manufacturer’s name. (TIF 2107 kb)
Additional file 2: Table S2. List of primers used for qPCR analyses. The
list of genes and details of the primers employed along with the expected
amplicon size and annealing temperature are provided. (PPTX 63 kb)
Additional file 3: Figure S1. In vitro aromatisation of testosterone (T)
and effects of AI on circulating E2 and P4 levels, weight of CL and
Cyp19a1 mRNA expression during rat pregnancy. (A) Sliced pieces of CL
tissue collected on day 7, 11, 12 and 16 of rat pregnancy was incubated
without or with 20 ng T for 4 h. E2 content in the medium was
estimated and represented as pg/mg tissue/4 h. Each bar represents
mean±SEM, n = 4 to 12/time point, ***P <0.001, *P <0.05. (B-E) Pregnant
rats received oral administration of AI (1 mg/kg BW) or VEH (2 % ethanol)
for four days daily. Circulating mean±SEM serum E2 (B) and P4 (C)
concentrations during different treatments (n = 5 to 10 animals/time
point, B and n = 3 animals/time point, C, **P <0.01, *P <0.05). (E) Weight
of CL during different treatments with a representative photo for each
treatment is shown on each bar (mean±SEM, n = 8 to 13 CL/time point)
(F) qPCR expression of Cyp19a1 mRNA in CL post different treatments.
The results are shown as fold changes of mRNA expression compared
to day 7 CL. Individual bars represents mean±SEM fold change in
mRNA expression value for qPCR analysis during different treatments
(n = 4 animals/time point). (PPTX 338 kb)
Additional file 4: Table S3. List of networks involved during
E2inhibition using Ingenuity Pathway Analysis (IPA). IPA was used to classify
the differentially expressed genes into different function and disease
categories. IPA on the differentially expressed genes for each of the
treatments examined and cross-talk and network overlapping were
determined. Networks were identified with score and number of
focus molecules ranging from as low as one to as high as 22 are repre-
sented. (PPTX 70 kb)
Additional file 5: Table S4. List of networks involved during E2
replacement AI+E2 using Ingenuity Pathway Analysis (IPA). IPA on the
differentially expressed genes for each of the treatments examined and
cross-talk and network overlapping are studied during E2 replacement
experiments are represented. (PPTX 72 kb)
Additional file 6: Figure S2. Classification of differentially expressed
genes associated with steroidogenesis and growth factors in response to
AI treatment. IPA of the differentially regulated genes post AI treatment
shows a network of 26 (steroidogenesis) and 16 (growth factors) focus
molecules. The network is displayed graphically as nodes (gene/gene
products) and edges (biological relationship between nodes). The node
colour intensity indicates the fold change expression of genes with red
representing up regulation and green, down regulation of genes. The
shapes of nodes indicate the functional class of the gene product and
the lines indicate the type of interaction. (PPTX 500 kb)
Additional file 7: Table S5. List of top 15 up regulated E2 responsive
genes post VEH or AI treatment. Potential E2 responsive genes in rat CL
were identified based on the available list of classical E2 responsive
genes, genes employed in PCR array human estrogen signalling and the
data base, ERGDB. Microarray data analysis was carried out to obtain
a set of differentially expressed genes based on statistics- Student’s t-test
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(two tail, unpaired) with P <0.05 and multiple hypothesis testing (Benjamini
and Hochberg comparison test) to reduce the false positives. The identified
differentially expressed E2 responsive genes were transcript consistent and
did not hybridize to multiple transcripts, as suggested by the AffyProbeMiner
analysis. A Bioconductor analysis was performed with ≤1.5 fold change
as cut-off and statistical filters for identification of differentially expressed E2
responsive genes. Top 15 UP regulated E2 responsive genes post VEH or AI
treatment are represented. Probe Set ID: The identifier that refers to a set of
probe pairs selected to represent expressed sequences on an array; Gene
symbol: Extracted from Entrez Gene or UniGene; Gene Title: Gene name
extracted from Entrez Gene or UniGene. (PPTX 83 kb)
Additional file 8: Table S6. List of top 15 up regulated E2 responsive
genes post AI or AI+E2 treatment Top 15 UP regulated E2 responsive
genes post AI or AI+E2 treatment are represented. (PPTX 85 kb)
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